{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:29:21Z","timestamp":1793212161213,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd000478.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000}}],"reference-count":124,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000478.pub5","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T06:39:27Z","timestamp":1740638367000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis"],"prefix":"10.1002","volume":"2025","author":[{"given":"Johannes","family":"Hasskamp","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Biometry; Carl von Ossietzky University of Oldenburg; Oldenburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Meinhardt","sequence":"additional","affiliation":[{"name":"Klinikum Oldenburg A\u00d6R, University Clinic for Internal Medicine - Gastroenterology; Oldenburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrease H","family":"Patton","sequence":"additional","affiliation":[{"name":"ER; London Health Sciences Center; London Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Timmer","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Biometry; Carl von Ossietzky University of Oldenburg; Oldenburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"6844","key":"10.1002\/14651858.CD000478.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/bmj.305.6844.20","article-title":"Randomised controlled trial of azathioprine withdrawal in ulcerative colitis","volume":"305","author":"Hawthorne","year":"1992","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1002\/14651858.CD000478.pub5-BIB0002|cit2","first-page":"323","article-title":"Azathioprine in ulcerative colitis","volume":"13","author":"Jewell","year":"1972","journal-title":"Gut"},{"issue":"5802","key":"10.1002\/14651858.CD000478.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/bmj.1.5802.709","article-title":"Azathioprine in ulcerative colitis: an interim report on a controlled therapeutic trial","volume":"1","author":"Jewell","year":"1972","journal-title":"British Medical Journal"},{"issue":"5945","key":"10.1002\/14651858.CD000478.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/bmj.4.5945.627","article-title":"Azathioprine in ulcerative colitis: final report on controlled therapeutic trial","volume":"4","author":"Jewell","year":"1974","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j","article-title":"Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial","volume":"45","author":"Kiszka-Kanowitz","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0006|cit6","unstructured":"L\u00f6wenberg M Volkers A van Gennep S Mookhoek A Montazeri N Clasquin E Mercaptopurine for the treatment of ulcerative colitis - a randomised placebo-controlled trial Manuscript Provided by Author"},{"issue":"Suppl V","key":"10.1002\/14651858.CD000478.pub5-BIB0007|cit7","first-page":"A132","article-title":"Methotrexate and 6-mercaptopurine in steroid-dependent inflammatory bowel disease patients: A randomized controlled clinical trial","volume":"45","author":"Hermida","year":"1999","journal-title":"Gut"},{"issue":"11","key":"10.1002\/14651858.CD000478.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00042737-200012110-00010","article-title":"6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease","volume":"12","author":"Mate-Jimenez","year":"2000","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"Suppl III A241","key":"10.1002\/14651858.CD000478.pub5-BIB0009|cit9","first-page":"P932","article-title":"Comparative effectiveness and safety of oral azathioprine and low-dose oral cyclosporin in maintenance of the response in patients with acute steroid-resistant ulcerative colitis","volume":"47","author":"Paraskeva","year":"2000","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD000478.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/apt.14106","article-title":"Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial","volume":"46","author":"Roblin","year":"2017","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD000478.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1744-9987.2012.01064.x","article-title":"Intermittent granulocyte and monocyte apheresis versus mercaptopurine for maintaining remission of ulcerative colitis: a pilot study","volume":"16","author":"Sakuraba","year":"2012","journal-title":"Therapeutic Apheresis and Dialysis"},{"issue":"1","key":"10.1002\/14651858.CD000478.pub5-BIB0012|cit12","first-page":"14","article-title":"Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial","volume":"19","author":"Sood","year":"2000","journal-title":"Indian Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD000478.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s005350200034","article-title":"The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis","volume":"37","author":"Sood","year":"2002","journal-title":"Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD000478.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00004836-199707000-00007","article-title":"Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis","volume":"25","author":"Ardizzone","year":"1997","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD000478.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gut.2005.068809","article-title":"Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis","volume":"55","author":"Ardizzone","year":"2006","journal-title":"Gut"},{"issue":"11","key":"10.1002\/14651858.CD000478.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1038\/ajg.2009.410","article-title":"Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal","volume":"104","author":"Cassinotti","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD000478.pub5-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.cgh.2019.08.034","article-title":"Genotype-based treatment with thiopurine reduces incidence of myelosuppression in patients with inflammatory bowel diseases","volume":"18","author":"Chang","year":"2020","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0018|cit18","unstructured":"Chao K Pre-genotype NUDT 15 R139C on reducing thiopurine-induced leucopenia in inflammatory bowel disease https:\/\/www.clinicaltrials.gov 2016"},{"issue":"2","key":"10.1002\/14651858.CD000478.pub5-BIB0019|cit19","first-page":"PI1","article-title":"Early onset steroid-dependent ulcerative colitis is a predictor of azathioprine response: a longitudinal 12-month follow-up study","volume":"16","author":"Chebli","year":"2010","journal-title":"Medical Science Monitor"},{"issue":"10","key":"10.1002\/14651858.CD000478.pub5-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1097\/MIB.0000000000001163","article-title":"More dose-dependent side effects with mercaptopurine over azathioprine in IBD treatment due to relatively higher dosing","volume":"23","author":"Broekman","year":"2017","journal-title":"Inflammatory Bowel Diseases"},{"issue":"2","key":"10.1002\/14651858.CD000478.pub5-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/MEG.0000000000001025","article-title":"Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients withinflammatory bowel diseases","volume":"30","author":"Broekman","year":"2018","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD000478.pub5-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/tpj.2016.87","article-title":"The glutathione transferase Mu null genotype leads to lower6-MMPR levels in patients treated with azathioprine but not with mercaptopurine","volume":"18","author":"Broekman","year":"2018","journal-title":"Pharmacogenomics Journal"},{"issue":"4","key":"10.1002\/14651858.CD000478.pub5-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1053\/j.gastro.2015.06.002","article-title":"Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease","volume":"149","author":"Coenen","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD000478.pub5-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/ecco-jcc\/jjz009","article-title":"Genotype-guided thiopurine dosing does not lead to additional costs in patients with inflammatory bowel disease","volume":"13","author":"Sluiter","year":"2019","journal-title":"Journal of Crohn's & Colitis"},{"issue":"3","key":"10.1002\/14651858.CD000478.pub5-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/apt.13879","article-title":"Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease","volume":"45","author":"Wong","year":"2017","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD000478.pub5-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/ecco-jcc\/jjw130","article-title":"Early assessment of thiopurine metabolites identifies patients at risk of thiopurine-induced leukopenia in inflammatory bowel disease","volume":"11","author":"Wong","year":"2017","journal-title":"Journal of Crohn's & Colitis"},{"issue":"5","key":"10.1002\/14651858.CD000478.pub5-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1542-3565(04)00127-2","article-title":"Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease","volume":"2","author":"Cuffari","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD000478.pub5-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1046\/j.1365-2036.2002.01385.x","article-title":"Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis","volume":"16","author":"Dom\u00e8nech","year":"2002","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"12","key":"10.1002\/14651858.CD000478.pub5-BIB0029|cit29","first-page":"2498","article-title":"Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis","volume":"91","author":"Fern\u00e1ndez-Ba\u00f1ares","year":"1996","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0030|cit30","unstructured":"Friedman AB Brookes JD Ward MG Headon B Nihill LN Reynolds J Adverse events to thiopurines can be overcome and the majority of patients respond to therapy - clinical outcomes from the EATME study Journal of Gastroenterology and Hepatology 2015 30 Suppl. 3 125 6"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/apt.14571","article-title":"Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine\/mercaptopurine nonresponders (AAA Study)","volume":"47","author":"Friedman","year":"2018","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"8","key":"10.1002\/14651858.CD000478.pub5-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s00535-003-1139-2","article-title":"Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis","volume":"38","author":"Hibi","year":"2003","journal-title":"Journal of Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD000478.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1007\/s10620-005-9037-5","article-title":"Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients","volume":"51","author":"Holtmann","year":"2006","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0034|cit34","unstructured":"Kim ES Azathioprine based on endoscopy after clinical remission in moderate to severe ulcerative colitis (ACE) ClinicalTrials.gov"},{"issue":"6325","key":"10.1002\/14651858.CD000478.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1136\/bmj.284.6325.1291","article-title":"Controlled trial of azathioprine in chronic ulcerative colitis","volume":"284","author":"Kirk","year":"1982","journal-title":"British Medical Journal"},{"issue":"12","key":"10.1002\/14651858.CD000478.pub5-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00365521.2016.1216589","article-title":"Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease","volume":"51","author":"Kiszka-Kanowitz","year":"2016","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD000478.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gutjnl-2016-313060","article-title":"Long-term outcome of patients with steroid- refractory acute severe UC treated with ciclosporin or infliximab","volume":"67","author":"Laharie","year":"2018","journal-title":"Gut"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0038|cit38","unstructured":"Evaluation of the clinical and immunological impact of two therapeutic strategies in chronic inflammatory diseases (STAMP) ClinicalTrials.gov"},{"issue":"8","key":"10.1002\/14651858.CD000478.pub5-BIB0039|cit39","first-page":"3328","article-title":"Nanoparticle methotrexate delivery system for the treatment of paediatric patients with inflammatory bowel disease","volume":"28","author":"Liu","year":"2017","journal-title":"Biomedical Research (Tokyo, Japan)"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0040|cit40","unstructured":"Logan R A randomised, open study of aminosalicylate withdrawal in patients with ulcerative colitis in established remission on combination treatment of azathioprine (or 6- mercaptopurine) and an aminosalicylate WHO ICTRP"},{"issue":"6","key":"10.1002\/14651858.CD000478.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1572-0241.2004.11481.x","article-title":"A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis","volume":"99","author":"Mantzaris","year":"2004","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0042|cit42","unstructured":"Conventional step-up versus infliximab monotherapy in patients with ulcerative colitis (P05553) (MUNIX) ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0043|cit43","unstructured":"Efficacy & safety of infliximab monotherapy vs combination therapy vs AZA monotherapy in ulcerative colitis (part 1) maintenance vs intermittent therapy for maintaining remission (part 2)(study P04807) ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0044|cit44","unstructured":"Nakase H Matsuura M Comparative study of Infliximab monotherapy vs combined therapy with azathiopurine for inducing and maintaining clinical remission in steroid-dependent or -resistant ulcerative colitis https:\/\/www.umin.ac.jp 2011"},{"issue":"2","key":"10.1002\/14651858.CD000478.pub5-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD000478.pub5-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1046\/j.1365-2036.2002.01340.x","article-title":"Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission","volume":"16","author":"Paoluzi","year":"2002","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"7","key":"10.1002\/14651858.CD000478.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/gutjnl-2019-319758","article-title":"Addition of azathioprine to the switch of anti-TNF inpatients with IBD in clinical relapse with undetectableanti-TNF trough levels and antidrug antibodies: aprospective randomised trial","volume":"69","author":"Roblin","year":"2020","journal-title":"Gut"},{"issue":"1","key":"10.1002\/14651858.CD000478.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0016-5085(19)32641-1","article-title":"A controlled trial of azathioprine in the management of chronic ulcerative colitis","volume":"69","author":"Rosenberg","year":"1975","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD000478.pub5-BIB0049|cit49","first-page":"147","article-title":"Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: Effect on cost and adverse events","volume":"19","author":"Sayani","year":"2005","journal-title":"Canadian Journal of Gastroenterology and Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD000478.pub5-BIB0050|cit50","first-page":"79","article-title":"Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis","volume":"22","author":"Sood","year":"2003","journal-title":"Indian Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD000478.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/ibd\/izy216","article-title":"The impact of thiopurine metabolite monitoring on the durability of thiopurine monotherapy in pediatric IBD","volume":"25","author":"Spencer","year":"2019","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0052|cit52","unstructured":"Suzuki Y Open-label, randomized, two-parallel-arm, single center study to designed to evaluate azathioprine versus adalimumab after induction of tacrolimus in refractory ulcerative colitis therapy https:\/\/www.umin.ac.jp 2018"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0053|cit53","unstructured":"Swanson G Chronotherapy in inflammatory bowel disease ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"Asati P Tripathi M Jain A Shukla S Dixit V Budhiraja S Comparative response of combination therapy vs. mono therapy in steroid dependent ulcerative colitis patients Inflammatory Bowel Diseases 2016 S39","DOI":"10.1097\/01.MIB.0000480201.06783.ab"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0055|cit55","unstructured":"SPRINT: An open-label, multicenter study to evalate step-up vs top-down treatment algorithms in moderate to severe ulcerative colitis clinicaltrialsregister.eu"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0056|cit56","unstructured":"Bodini G Savarino V Dulbecco P Baldissarro I Savarino E IBD recurrence after stopping anti-TNF-alpha therapy: a prospective randomized controlled study comparing mesalamine and azathioprine - ad interim results United European Gastroenterology Journal 2014 2 1S A214 A215"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0057|cit57","unstructured":"Leong R Vedolizumab blood levels with or without immunomodulators in patients with ulcerative colitis https:\/\/www.anzctr.org.au 2018"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0058|cit58","unstructured":"Sahu P Treatment of patients with ulcerative colitis http:\/\/www.ctri.nic.in 2020"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0059|cit59","unstructured":"Ahuja V Efficacy and tolerability of Azathioprine and Methotrexate for maintenance of remission in Ulcerative colitis - A Randomized Control Study http:\/\/www.ctri.nic.in 2017"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0060|cit60","unstructured":"Ahuja V A study to compare the effectiveness and safety of high standard dose with low start up dose strategy of azathioprine in patients with ulcerative colitis https:\/\/www.ctri.nic.in 2020"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0061|cit61","unstructured":"Danese S Fiorino G Two therapeutic strategies for the maintenance of remission in patients with ulcerative colitis (SCILLA) https:\/\/www.clinicaltrials.gov 2017"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0062|cit62","unstructured":"Halfvarsson J NORDTREAT The Nordic IBD treatment strategy trial - a randomized controlled trial of access to a protein profile https:\/\/www.clinicaltrialsregister.eu 2021"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0063|cit63","unstructured":"Irving P Rahman A Subcutaneous CT-P13 monotherapy versus combination with immunomodulation when switching from intravenous infliximab in inflammatory bowel disease - A multicentre, randomised withdrawal trial WHO ICTRP 2022"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0064|cit64","unstructured":"Karling P Low-dose azathioprine and allopurinol- versus azathioprine monotherapy in patients with Inflammatory Bowel Disease: An investigator-initiated, open, multicentre, parallel-arm, randomized controlled trial https:\/\/www.clinicaltrialregister.eu 2016"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD000478.pub5-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jgh.15271","article-title":"De novo combination allopurinol-thiopurine versus standard thiopurine in inflammatory bowel disease patients escalating to immunomodulators: A randomized controlled trial (DECIDER study)","volume":"35","author":"Vasudevan","year":"2020","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD000478.pub5-BIB0066|cit66","first-page":"1","article-title":"Traditional Chinese medicine combination therapy for patients with steroid- dependent ulcerative colitis: study protocol for a randomized controlled trial","volume":"18","author":"Zheng","year":"2017","journal-title":"Trials"},{"issue":"11","key":"10.1002\/14651858.CD000478.pub5-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: inflammatory bowel disease and malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"Journal of Crohn's & Colitis"},{"issue":"6","key":"10.1002\/14651858.CD000478.pub5-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1365-2036.2009.04221.x","article-title":"Low-dose azathioprine or mercaptopurine in combination withallopurinol can bypass many adverse drug reactions in patientswith inflammatory bowel disease","volume":"31","author":"Ansari","year":"2010","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"46","key":"10.1002\/14651858.CD000478.pub5-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"10103","DOI":"10.3748\/wjg.v22.i46.10103","article-title":"Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective","volume":"22","author":"Axelrad","year":"2016","journal-title":"World Journal of Gastroenteroly"},{"issue":"9","key":"10.1002\/14651858.CD000478.pub5-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11894-020-00781-3","article-title":"Hepatotoxicty of agents used in the management of inflammatory bowel disease: a 2020 update","volume":"22","author":"Barnhill","year":"2020","journal-title":"Current Gastroenteroly Reports"},{"issue":"6","key":"10.1002\/14651858.CD000478.pub5-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.1966.03100060100027","article-title":"Early experiences with azathioprine in ulcerative colitis; a note of caution","volume":"195","author":"Bowen","year":"1966","journal-title":"Journal of the American Medical Association"},{"issue":"37","key":"10.1002\/14651858.CD000478.pub5-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.3748\/wjg.v17.i37.4166","article-title":"Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease","volume":"17","author":"Bradford","year":"2011","journal-title":"World Journal of Gastroenteroly"},{"issue":"10","key":"10.1002\/14651858.CD000478.pub5-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1136\/gutjnl-2021-326390","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","volume":"71","author":"Burr","year":"2021","journal-title":"Gut"},{"issue":"7","key":"10.1002\/14651858.CD000478.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","article-title":"Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients","volume":"19","author":"Chaparro","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"issue":"7","key":"10.1002\/14651858.CD000478.pub5-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/apt.13102","article-title":"Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis","volume":"41","author":"Christophorou","year":"2015","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"8","key":"10.1002\/14651858.CD000478.pub5-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/apt.16050","article-title":"Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory bowel disease","volume":"52","author":"Chupin","year":"2020","journal-title":"Alimentary Pharmacology & Therpeutics"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0077|cit77","unstructured":"Covidence systematic review software Veritas Health Innovation 2021"},{"issue":"5","key":"10.1002\/14651858.CD000478.pub5-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/ecco-jcc\/jjx181","article-title":"Thiopurines in inflammatory bowel disease: new findings and perspectives","volume":"12","author":"De Boer","year":"2018","journal-title":"Journal of Crohn's & Colitis"},{"issue":"4","key":"10.1002\/14651858.CD000478.pub5-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.gtc.2020.07.005","article-title":"Epidemiology and pathogenesis of ulcerative colitis","volume":"49","author":"Du","year":"2020","journal-title":"Gastroenteroly Clinics of North America"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0080|cit80","unstructured":"European Medicines Agency EU\/3\/09\/694 - orphan designation for treatment of acute lymphoblastic leukaemiaShare https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-09-694 2009"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0081|cit81","unstructured":"TABLOID- thioguanine tablet Aspen Global Inc https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/012429s028lbl.pdf 2018"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0082|cit82","unstructured":"Ulcerative Colitis: Developing Drugs for Treatment Guidance for Industry. Draft Guidance https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/ulcerative-colitis-developing-drugs-treatment 2022"},{"issue":"7","key":"10.1002\/14651858.CD000478.pub5-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.mayocp.2019.01.018","article-title":"Ulcerative colitis","volume":"94","author":"Feuerstein","year":"2019","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0084|cit84","doi-asserted-by":"crossref","unstructured":"Feuerstein JD Isaacs KL Schneider Y Siddique SM Singh S AG Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis Gastroenterology 2020 158 1450 1461","DOI":"10.1053\/j.gastro.2020.01.006"},{"issue":"2","key":"10.1002\/14651858.CD000478.pub5-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1365-2036.2009.04023.x","article-title":"Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis","volume":"30","author":"Gisbert","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/7247238","article-title":"A comprehensive review and update on the pathogenesis of inflammatory bowel disease","volume":"2019","author":"Guan","year":"2019","journal-title":"Journal of Immunology Research"},{"issue":"7650","key":"10.1002\/14651858.CD000478.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"British Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD000478.pub5-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"612","DOI":"10.20524\/aog.2021.0645","article-title":"Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis","volume":"34","author":"Hashash","year":"2021","journal-title":"Annals of Gastroenterology"},{"issue":"7414","key":"10.1002\/14651858.CD000478.pub5-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"British Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD000478.pub5-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/ibd.23021","article-title":"Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease","volume":"19","author":"Hoentjen","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"issue":"7","key":"10.1002\/14651858.CD000478.pub5-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"102155","DOI":"10.1016\/j.clinre.2023.102155","article-title":"Effectiveness and safety of thioguanine as a maintenance therapy of inflammatory bowel disease: Systematic review, meta-analysis and meta-regression","volume":"47","author":"Jena","year":"2023","journal-title":"Clinics and Research in Hepatology and Gastroenterology"},{"issue":"5945","key":"10.1002\/14651858.CD000478.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/bmj.4.5945.627","article-title":"Azathioprine in ulcerative colitis: final report on controlled therapeutic trial","volume":"4","author":"Jewell","year":"1974","journal-title":"British Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD000478.pub5-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","article-title":"Understanding and preventing the global increase of inlammatory bowel disease","volume":"152","author":"Kaplan","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD000478.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s11938-019-00244-3","article-title":"The evolving role of thiopurines in inflammatory bowel disease","volume":"17","author":"Kapur","year":"2019","journal-title":"Current Treatment Options in Gastroenteroly"},{"issue":"4","key":"10.1002\/14651858.CD000478.pub5-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/ajg.2011.64","article-title":"Efficacy of immunosuppressive therapy for inflammatory bowel disease:a systematic review and meta-analysis","volume":"106","author":"Khan","year":"2011","journal-title":"American Journal of Gastroenteroly"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0096|cit96","unstructured":"Kucharzik T Dignass A Atreya R Bokemeyer B Esters P Herrlinger K Updated S3 Guideline Ulcerative Colitis (Version 6.1) Deutsche Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten 2023 https:\/\/www.dgvs.de\/wissen\/leitlinien\/leitlinien-dgvs\/colitis-ulcerosa"},{"issue":"e21","key":"10.1002\/14651858.CD000478.pub5-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1053\/j.gastro.2020.10.065","article-title":"Selecting end points for disease-modification trials in inflammatory bowel disease: the SPIRIT consensus from the IOIBD","volume":"160","author":"Le Berre","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD000478.pub5-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.cgh.2017.08.025","article-title":"Heterogeneity in definitions of endpoints for clinical trials of ulcerative colitis: a systematic review for development of a core outcome set","volume":"16","author":"Ma","year":"2018","journal-title":"Clinical Gastroenteroly and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD000478.pub5-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11938-017-0128-0","article-title":"Thiopurines and methotrexate use in IBD patients in a biologic era","volume":"15","author":"Mantzaris","year":"2017","journal-title":"Current Treatment Options in Gastroenteroly"},{"issue":"10114","key":"10.1002\/14651858.CD000478.pub5-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/s0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD000478.pub5-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1007\/s10620-020-06662-z","article-title":"Evolving role of thiopurines in inflammatory bowel disease in the era of biologics and new small molecules","volume":"66","author":"Nguyen","year":"2020","journal-title":"Digestive Diseases and Sciences"},{"issue":"2","key":"10.1002\/14651858.CD000478.pub5-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD000478.pub5-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD000478.pub5-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"Journal of Crohn's & Colitis"},{"issue":"5","key":"10.1002\/14651858.CD000478.pub5-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0106|cit106","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2023"},{"issue":"7","key":"10.1002\/14651858.CD000478.pub5-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/gutjnl-2019-319758","article-title":"Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial","volume":"69","author":"Roblin","year":"2020","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD000478.pub5-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"American Journal of Gastroenteroly"},{"issue":"26","key":"10.1002\/14651858.CD000478.pub5-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminsalicylic acid therapy for mildly to moderately active ulcerative colitis","volume":"317","author":"Schroeder","year":"1987","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0110|cit110","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) The Cochrane Collaboration"},{"issue":"1","key":"10.1002\/14651858.CD000478.pub5-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD000478.pub5-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.dld.2021.05.038","article-title":"Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease","volume":"53","author":"Sousa","year":"2021","journal-title":"Digestive and Liver Disease"},{"issue":"5","key":"10.1002\/14651858.CD000478.pub5-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1365-2036.2005.02583.x","article-title":"Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine","volume":"22","author":"Sparrow","year":"2005","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD000478.pub5-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cgh.2006.11.020","article-title":"Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine","volume":"5","author":"Sparrow","year":"2007","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD000478.pub5-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"I4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"British Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD000478.pub5-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/ecco-jcc\/jjv188","article-title":"Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases--A prospective study on incidence and severity","volume":"10","author":"Teich","year":"2016","journal-title":"Journal of Crohn's & Colitis"},{"issue":"8","key":"10.1002\/14651858.CD000478.pub5-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1172\/jci200316432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"Journal of Clinical Investigation"},{"issue":"5","key":"10.1002\/14651858.CD000478.pub5-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"10080","key":"10.1002\/14651858.CD000478.pub5-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD000478.pub5-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/apt.15403","article-title":"Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD","volume":"50","author":"Gennep","year":"2019","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD000478.pub5-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"218","DOI":"10.5217\/ir.2016.14.3.218","article-title":"Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries","volume":"14","author":"Wei","year":"2016","journal-title":"Intestinal Research"},{"issue":"1","key":"10.1002\/14651858.CD000478.pub5-BIB0122|cit122","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000478.pub2","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","author":"Timmer","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD000478.pub5-BIB0123|cit123","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000478.pub3","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","author":"Timmer","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD000478.pub5-BIB0124|cit124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000478.pub4","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","author":"Timmer","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T08:32:42Z","timestamp":1785313962000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD000478.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":124,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000478.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}